Research programme: GPR40-GPR120 dual agonists - Advinus Therapeutics
Latest Information Update: 28 Feb 2020
At a glance
- Originator Advinus Therapeutics
- Class
- Mechanism of Action FFAR1 protein stimulants; GPR120 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Type-2-diabetes-mellitus in India
- 25 Jan 2016 GPR40-GPR120 dual agonists - Advinus Therapeutics is available for licensing as of 25 Jan 2016. www.advinus.com
- 25 Jan 2016 Early research in Type-2 diabetes mellitus in India (unspecified route)